COVID-19 / 95% of US Rare Disease Patients Affected
As of 11 June 2020, there have been over two million confirmed cases of COVID-19 in the US and over 115,000 deaths, with the US having occupied the leading spot…
Address: 781 Chestnut Ridge Rd, Morgantown, WV 26505,United States of America
Tel: 1-800-RX-MYLAN
Mylan Pharmaceuticals, a subsidiary of Mylan Inc. based in Morgantown, W.Va., is a market leader in researching, developing, manufacturing, marketing and distributing generic pharmaceutical products in a variety of sophisticated dosage forms. Since 1961, Mylan Pharmaceuticals has held a long-standing reputation for quality, integrity and exemplary service and has maintained its commitment to increasing and protecting consumer access to affordable pharmaceuticals.
Mylan Pharmaceuticals has one of the largest product portfolios in the U.S., consisting of more than 200 products. According to IMS Health, one of every 12 prescriptions dispensed in the U.S. is a Mylan product.1 The company pioneered and continues to specialize in groundbreaking delivery technologies and difficult-to-manufacture and -formulate pharmaceuticals that treat diseases ranging from angina to arthritis, depression to diabetes, pain to Parkinson’s disease, and schizophrenia to sleep disorders.
As of 11 June 2020, there have been over two million confirmed cases of COVID-19 in the US and over 115,000 deaths, with the US having occupied the leading spot…
Peter L Saltonstall, president and CEO of the US National Organization for Rare Disorders (NORD) shares the organization’s key priorities, what makes NORD a unique patient advocacy group in the…
Three US country managers for European pharma mid-caps explain the challenges in setting up an American affiliate, as well as how best to capitalise on the abundant opportunities in the…
At the 28 May 2020 IFPMA media briefing on COVID-19 vaccines, Pfizer chairman and CEO Dr Albert Bourla outlined why the US firm had decided to take a different tack…
Jose Antonio Moreno Toscano, CEO for the US affiliate of iconic French firm LFB shares the company’s journey in the US market and his insights for other European mid-caps looking…
Dr Gerard Anderson of Johns Hopkins University Bloomberg School of Public Health critiques the US response to the COVID-19 pandemic, before explaining how access and affordability in the US can…
In a recent interview with Financial Times, Sanofi CEO Paul Hudson set out to clarify some recent comments that the US would get priority access to a COVID-19 vaccine. He…
Jorge Alderete, president of ALK Americas, recently spoke to PharmaBoardroom about his 20+ years with the Danish mid-cap, the challenges in communicating the USA’s challenging market access environment to a…
Jorge Alderete, president of ALK Americas, outlines the Danish mid-cap’s strategy in the challenging US market, including innovative market access initiatives, and how future models of patient-doctor interaction and medical…
Carol Lynch, president of Sandoz US and head of Sandoz North America, recently spoke exclusively to PharmaBoardroom about how her diverse global experiences in innovative biopharma and biosimilars are informing…
Carol Lynch of Sandoz US talks candidly on the US generics market from an international perspective, market access, biosimilars uptake, talent attraction, and navigating the COVID-19 crisis. The US…
DataArt’s Daniel Piekarz looks at how machine learning and artificial intelligence can play into the important task of drug repurposing, potentially providing solutions to the most pressing healthcare concerns of…
See our Cookie Privacy Policy Here